In this context, concurrent inhibition of AKT and MEK signaling has been shown to be effective in inducing regressions of mutant Kras-driven murine lung adenocarcinomas [2] and this strategy is being evaluated for the treatment of patients with mutant KRAS NSCLC. Here, AKT1 is linked to lung adenocarcinoma.